A perspective of sensor-augmented insulin pump therapy in the treatment of type 1 diabetes

The holy grail for the treatment of type 1 diabetes is stem cell therapy (1,2) or the closed-loop artificial pancreas (3,4). Whereas several groups are currently developing these treatment modalities, they are not there yet. The first step in the process has been met with the low-glucose suspend pump, which stops insulin delivery for up to 2 hours when the interstitial glucose concentration reaches 70 mg/dL. The Diabetes Control and Complications Trial first showed a clear relationship between diabetic microvascular complications and glycemic control. Others have posited data supporting a relationship between macrovascular disease and glycemic control. In addition to achieving an optimum glycated hemoglobin (HbA1c) level of